Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Developing a Tiered Immunogenicity Testing Strategy for ADCs According to Paul-Ehrlich-Institut Recommendations

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Developing a Tiered Immunogenicity Testing Strategy for ADCs According to Paul-Ehrlich-Institut Recommendations

Tiered Immunogenicity Testing for Antibody-Based Bioconjugates: Aligning with Paul-Ehrlich-Institut Guidance

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    What is the primary difference between PEI and other regulatory guidance on immunogenicity for complex bioconjugates?

    A: The Paul-Ehrlich-Institut (PEI) places a significant emphasis on understanding the domain specificity of the anti-drug antibody (ADA) response. This requires assays capable of distinguishing whether immunogenicity is directed against the monoclonal antibody backbone, the cytotoxic payload, the linker, or neoantigens formed at the conjugation site.

    How does the linker-payload component influence the tiered testing strategy?

    A: The linker and payload can be immunogenic on their own or create novel epitopes. This necessitates a highly sensitive screening assay and a confirmation assay with specific competitive reagents to verify the ADA response. It also introduces potential assay matrix interference that must be rigorously evaluated during method development.

    What are the key considerations for developing a neutralizing antibody (NAb) assay for an antibody-payload conjugate?

    A: The NAb assay must reflect the biologic’s specific mechanism of action (MoA). For a bioconjugate designed for payload delivery, a cell-based assay measuring cytotoxicity or another relevant downstream biological effect is typically required. A simple binding assay is insufficient to characterize neutralizing potential.

    When should ADA domain specificity analysis be implemented?

    A: Domain specificity characterization is an integral part of the characterization tier and must be performed on all confirmed ADA-positive samples. This analysis provides data for regulatory submissions to German authorities, as it clarifies the precise nature of the immune response.

A robust, tiered immunogenicity testing strategy is a central component of any successful biologics program. For developers of antibody-based bioconjugates targeting the European market, particularly Germany, aligning this strategy with the specific expectations of the Paul-Ehrlich-Institut from the outset is a program-defining decision. The PEI’s focus on domain specificity and MoA-reflective neutralizing antibody assays requires a more nuanced approach than standard monoclonal antibody testing. This involves developing and validating a suite of assays that can dissect the immune response to each component of the complex molecule: the antibody, the linker, and the payload.

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

Foundational Principles of the Tiered Approach

The multi-tiered framework for immunogenicity assessment provides a systematic method for identifying and characterizing anti-drug antibodies. This workflow is designed to manage sample volume efficiently while ensuring no clinically relevant immune response is missed.

  • Screening: A high-sensitivity assay is used to test all relevant subject samples to identify potential ADA-positive results. The goal is to minimize false negatives.

  • Confirmation: Potentially positive samples from the screening tier undergo a confirmatory assay. This step uses specific competitive inhibition to distinguish true ADA binding from non-specific matrix effects, minimizing false positives.

  • Titration & Neutralization: Confirmed positive samples are then analyzed to determine the magnitude of the ADA response (titer) and its functional consequence via a neutralizing antibody assay.

PEI-Specific Considerations for Conjugated Biologics

While the tiered structure is globally accepted, the PEI’s guidance requires deeper characterization for complex biologics. The conjugation of a payload to an antibody backbone can introduce new immunogenic risks that must be proactively investigated. Regulatory submissions require a clear understanding of which part of the molecule is driving any observed immunogenicity.

This level of detail is central to our approach, providing the Immunogenicity Intelligence for Advanced Therapies required for complex filings. We design confirmatory and characterization assays that can pinpoint the ADA response to the antibody framework versus the linker-payload complex. This is achieved through the use of precisely engineered competitive binding reagents in the assay format.

A close-up of a scientist in blue gloves gently holding a small, white laboratory mouse, likely in a research setting.

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

Integrating Predictive Analytics and Translational Insights

A modern immunogenicity strategy incorporates data beyond the wet lab. Insights from predictive analytics can inform initial risk assessments. As demonstrated in studies using machine learning to identify risk predictors for complex biological outcomes (PMID: 30342683), computational tools can help identify potential immunogenic hotspots in a molecule’s sequence before assays are even developed.

A parallel concept is seen in complex vaccine research, where distinct elements of a multi-component biologic can elicit strong and specific humoral and cellular responses (PMID: 12533717). This principle directly translates to antibody-payload conjugates, reinforcing the PEI’s expectation that a program must be able to differentiate between immunity to the delivery vehicle and the active payload.

Programmatic Support for European Filings

At our >100,000 sq ft GxP-compliant facility, we build bioanalytical packages designed for regulatory success. Our teams focus on developing these nuanced assay strategies early to support an accelerated 18-24 month IND timeline. This proactive, regulator-focused approach reflects the track record of our core scientific team, whose programs have achieved a 100% IND success rate since 2019. Note: The Franklin Biolabs brand was launched in 2024.

Standard Tiered Approach PEI-Aligned Strategy (Franklin Biolabs)
Generic ADA Screening Assay Highly Sensitive Screening Assay
Single Confirmatory Step Confirmatory Assay with Domain-Specific Reagents
Ligand-Binding NAb Assay MoA-Reflective, Cell-Based NAb Assay
Characterization as an Add-On Integrated Domain Specificity & Isotyping

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities